Evidence map›Paper›PMID 23863452›Full record

ArticleBiomaterials2013

The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption.

Huining He, Jianyong Sheng, Allan E David, Young Min Kwon, Jian Zhang, Yongzhuo Huang, Jianxin Wang, Victor C Yang

Abstract read
In one paragraph

Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Article
  19. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Huining HeTianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
Jianyong Sheng
Allan E David
Young Min Kwon
Jian Zhang
Yongzhuo Huang
Jianxin Wang
Victor C Yang
Fudan University · CNTianjin Medical University · CNAuburn University · USNova Southeastern University · USUniversity of Michigan–Ann Arbor · US

Funding

PTD-Mediated Protein or Drug Delivery for Cancer TherapyR01CA114612 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YANG, VICTOR C · 2005 to 2015
$2.5M
NCI NIH HHS R01 CA114612
6 · The paper itself

Abstract

Although oral delivery of insulin offers a number of unmatched advantages, it nevertheless is beset by the poor permeability of insulin molecules through the epithelial cell membranes of the intestinal mucosal layer. We previously reported the development of low molecular weight protamine (LMWP) as a non-toxic yet potent cell-penetrating peptide, of which via covalent linkage was capable of translocating protein cargos through the membranes of almost all cell types. It is therefore hypothesized that LMWP could be practically employed as a safe and effective tool to deliver insulin across the intestinal mucosal membrane, thereby augmenting its absorption through the GI tract. However, formulating 1:1 monomeric insulin/LMWP conjugate presents a tall order of challenge, as the acidic insulin and basic LMWP would automatically form tight aggregates through electrostatic interactions. In this paper, we developed an innovative conjugation strategy to solve this problem, by using succinimidyl-[(N-maleimidopropionamido)-polyethyleneglycol] ester (NHS-PEG-MAL) as an intermediate cross-linker during the coupling process. Both SDS-PAGE and MALDI-TOF mass spectroscopy confirmed the formation of a homogenous, monomeric (1:1 ratio) insulin/LMWP conjugate without encountering the conventional problem of substrate aggregation. Cell culture studies demonstrated that transport of the Insulin-PEG-LMWP conjugate across the intestinal mucosal monolayer was augmented by almost five-folds compared to native insulin. Furthermore, results from the in situ loop absorption tests in rats showed that systemic pharmacological bioavailability of insulin was significantly enhanced after its conjugation with LMWP. Overall, the presented chemical conjugation with LMWP could offer a reliable and safe means to improve the intestinal permeability of therapeutic peptides/proteins, shedding light of the possibility for their effective oral delivery.

Indexed as

AnimalsCaco-2 CellsElectrophoresis, Polyacrylamide GelHumansInsulinIntestinal AbsorptionMaleMolecular WeightProtaminesRatsRats, WistarSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationInsulinProtaminesCell-penetrating peptideInsulinIntestinal absorptionLow molecular weight protamineMonomeric conjugationPermeation enhancement

Identifiers

PMID23863452
PMCPMC3766633
OpenAlexW2130036809

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.